3:44 PM
 | 
Aug 22, 2017
 |  BC Extra  |  Financial News

AAT deficiency newco Apic Bio launches

Gene therapy company Apic Bio Inc. (Cambridge, Mass.) launched Tuesday with an undisclosed investment from the Alpha-1 Foundation and private investor Ed Krapels, who has alpha-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency.

The company said its lead AAT deficiency candidate, APB-101, has achieved preclinical proof of...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >